Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI107995

Ethacrynic Acid EFFECTS ON THE COCHLEAR POTENTIALS IN NORMAL AND HIGH BLOOD OXYGEN

Jiri Prazma and John B. Pecorak

1Department of Surgery, Division of Otolaryngology, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27514

Find articles by Prazma, J. in: PubMed | Google Scholar

1Department of Surgery, Division of Otolaryngology, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27514

Find articles by Pecorak, J. in: PubMed | Google Scholar

Published April 1, 1975 - More info

Published in Volume 55, Issue 4 on April 1, 1975
J Clin Invest. 1975;55(4):840–844. https://doi.org/10.1172/JCI107995.
© 1975 The American Society for Clinical Investigation
Published April 1, 1975 - Version history
View PDF
Abstract

The effect of ethacrynic acid (EA) at different blood O2 saturations on cochlear potentials of guinea pigs was investigated. All 18 young healthy guinea pigs received 50 mg/kg/h of EA intravenously and were divided into three groups: first group, normal (90.00±6.30-86.17±4.83 mm Hg); second group, lower Po2 (78.00±4.74-70.00±4.42 mm Hg); and third group, high Po2 (174.40±13.41-179.00±26.15 mm Hg). The partial pressure of oxygen (Po2), the partial pressure of carbon dioxide (Pco2), and the pH of the blood were measured before EA administration and at the end of the experiment (3 h later) by drawing blood samples from the contralateral carotid artery. Cochlear potentials—endocochlear potential (EP), cochlear microphonics (CM), and action potentials (AP)—were recorded by standard methods from the first turn of the cochlea. Experimental data seem to indicate that elevation of the Po2 to 174-179 mm Hg during relatively high doses of EA treatment prevents the declines in cochlear potentials which were observed in the first and second groups (normal and lower Po2), and preserves active ion transport which is responsible for the generation of cochlear potentials. These data suggest a means by which to reduce the ototoxic effect of EA and possibly indicates a method of treatment for hearing loss which developed after the administration of EA.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 840
page 840
icon of scanned page 841
page 841
icon of scanned page 842
page 842
icon of scanned page 843
page 843
icon of scanned page 844
page 844
Version history
  • Version 1 (April 1, 1975): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts